ERBB2 and breast carcinoma: They found that HER2-positive breast cancer cells express neuromedin U(NmU), which blocks the immune response and promotes the expression of immunosuppressive molecules, such as TGFβ1., therefore functionally affecting ADCC and inducing trastuzumab resistance.